Monoamine oxidase inhibitors

Safety and efficacy issues

Candace Brown, S. G. Bryant

Research output: Contribution to journalReview article

26 Citations (Scopus)

Abstract

Controversy has historically centered on the use of monoamine oxidase inhibitors (MAOI) in the treatment of depression because of safety and efficacy issues. Hypertensive crisis following ingestion of foods containing tyramine is the most feared problem associated with MAOI therapy. The authors conclude that only four tyramine-containing foods clearly warrant absolute prohibition, but indicate situations where moderation should apply. Although MAOI remain second-line agents in the treatment of endogenous depression, it is unclear whether MAOI or tricyclic antidepressants should be the drugs of choice in atypical depression and this question necessitates future research.

Original languageEnglish (US)
Pages (from-to)232-235
Number of pages4
JournalDrug Intelligence and Clinical Pharmacy
Volume22
Issue number3
DOIs
StatePublished - Jan 1 1988

Fingerprint

Monoamine Oxidase Inhibitors
Safety
Tyramine
Depression
Food
Tricyclic Antidepressive Agents
Depressive Disorder
Eating
Pharmaceutical Preparations
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Pharmacology (medical)

Cite this

Monoamine oxidase inhibitors : Safety and efficacy issues. / Brown, Candace; Bryant, S. G.

In: Drug Intelligence and Clinical Pharmacy, Vol. 22, No. 3, 01.01.1988, p. 232-235.

Research output: Contribution to journalReview article

@article{7299fedb78564ed09fb28cc62d7842a0,
title = "Monoamine oxidase inhibitors: Safety and efficacy issues",
abstract = "Controversy has historically centered on the use of monoamine oxidase inhibitors (MAOI) in the treatment of depression because of safety and efficacy issues. Hypertensive crisis following ingestion of foods containing tyramine is the most feared problem associated with MAOI therapy. The authors conclude that only four tyramine-containing foods clearly warrant absolute prohibition, but indicate situations where moderation should apply. Although MAOI remain second-line agents in the treatment of endogenous depression, it is unclear whether MAOI or tricyclic antidepressants should be the drugs of choice in atypical depression and this question necessitates future research.",
author = "Candace Brown and Bryant, {S. G.}",
year = "1988",
month = "1",
day = "1",
doi = "10.1177/106002808802200311",
language = "English (US)",
volume = "22",
pages = "232--235",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "3",

}

TY - JOUR

T1 - Monoamine oxidase inhibitors

T2 - Safety and efficacy issues

AU - Brown, Candace

AU - Bryant, S. G.

PY - 1988/1/1

Y1 - 1988/1/1

N2 - Controversy has historically centered on the use of monoamine oxidase inhibitors (MAOI) in the treatment of depression because of safety and efficacy issues. Hypertensive crisis following ingestion of foods containing tyramine is the most feared problem associated with MAOI therapy. The authors conclude that only four tyramine-containing foods clearly warrant absolute prohibition, but indicate situations where moderation should apply. Although MAOI remain second-line agents in the treatment of endogenous depression, it is unclear whether MAOI or tricyclic antidepressants should be the drugs of choice in atypical depression and this question necessitates future research.

AB - Controversy has historically centered on the use of monoamine oxidase inhibitors (MAOI) in the treatment of depression because of safety and efficacy issues. Hypertensive crisis following ingestion of foods containing tyramine is the most feared problem associated with MAOI therapy. The authors conclude that only four tyramine-containing foods clearly warrant absolute prohibition, but indicate situations where moderation should apply. Although MAOI remain second-line agents in the treatment of endogenous depression, it is unclear whether MAOI or tricyclic antidepressants should be the drugs of choice in atypical depression and this question necessitates future research.

UR - http://www.scopus.com/inward/record.url?scp=0023873784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023873784&partnerID=8YFLogxK

U2 - 10.1177/106002808802200311

DO - 10.1177/106002808802200311

M3 - Review article

VL - 22

SP - 232

EP - 235

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 3

ER -